These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 16236860)

  • 41. Relevance of soft-tissue penetration by levofloxacin for target site bacterial killing in patients with sepsis.
    Zeitlinger MA; Dehghanyar P; Mayer BX; Schenk BS; Neckel U; Heinz G; Georgopoulos A; Müller M; Joukhadar C
    Antimicrob Agents Chemother; 2003 Nov; 47(11):3548-53. PubMed ID: 14576116
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections.
    Ambrose PG; Grasela DM; Grasela TH; Passarell J; Mayer HB; Pierce PF
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2793-7. PubMed ID: 11557471
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tear concentration and safety of levofloxacin ophthalmic solution 1.5% compared with ofloxacin ophthalmic solution 0.3% after topical administration in healthy adult volunteers.
    Walters T; Rinehart M; Krebs W; Holdbrook M
    Cornea; 2010 Mar; 29(3):263-8. PubMed ID: 20098307
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Update on the use of levofloxacin in the management of acute exacerbations of chronic bronchitis with risk factors].
    Zuck P
    Presse Med; 2002 Jun; 31(21 Pt 2):S15-8. PubMed ID: 12148385
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacodynamics: relation to antimicrobial resistance.
    Rybak MJ
    Am J Infect Control; 2006 Jun; 34(5 Suppl 1):S38-45; discussion S64-73. PubMed ID: 16813981
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Penetration of levofloxacin into the anterior chamber (aqueous humour) of the human eye after intravenous administration.
    García-Vázquez E; Mensa J; Sarasa M; López Y; Couchard PD; Soy D; Fontenla JR
    Eur J Clin Microbiol Infect Dis; 2007 Feb; 26(2):137-40. PubMed ID: 17216423
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Laboratory and clinical studies on levofloxacin].
    Tanaka K; Iwamoto M; Maesaki S; Koga H; Kohno S; Hara K; Sugawara K; Kaku M; Kusano S; Sakito O
    Jpn J Antibiot; 1992 May; 45(5):548-56. PubMed ID: 1512941
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Penetration of levofloxacin into paranasal sinuses mucosa of patients with chronic rhinosinusitis after a single 500 mg oral dose.
    Pea F; Marioni G; Pavan F; Staffieri C; Bottin R; Staffieri A; Furlanut M
    Pharmacol Res; 2007 Jan; 55(1):38-41. PubMed ID: 17092740
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics, urinary excretion and dosage regimen of levofloxacin following a single intramuscular administration in cross bred calves.
    Dumka VK; Srivastava AK
    J Vet Sci; 2006 Dec; 7(4):333-7. PubMed ID: 17106223
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The first 'respiration' fluoroquinolone--levofloxacin (Tavanic) in therapy of bacterial infections. Pharmacodynamics principles in optimization of administration regimens].
    Budanov SV; Vasil'ev AN; Smirnova LB
    Antibiot Khimioter; 2001; 46(7):38-46. PubMed ID: 11697244
    [No Abstract]   [Full Text] [Related]  

  • 51. [Levofloxacin concentrations in serum, sputum and lung tissue: evaluation of its efficacy according to breakpoint].
    Fujita A; Miya T; Tanaka R; Hirayama S; Isaka H; Ono Y; Koshiishi Y; Goya T
    Jpn J Antibiot; 1999 Nov; 52(11):661-6. PubMed ID: 10659442
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacodynamics of tobramycin in patients with cystic fibrosis.
    Mouton JW; Jacobs N; Tiddens H; Horrevorts AM
    Diagn Microbiol Infect Dis; 2005 Jun; 52(2):123-7. PubMed ID: 15964500
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Altered steady state pharmacokinetics of levofloxacin in adult cystic fibrosis patients receiving calcium carbonate.
    Pai MP; Allen SE; Amsden GW
    J Cyst Fibros; 2006 Aug; 5(3):153-7. PubMed ID: 16481224
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of azithromycin vs levofloxacin in the outpatient treatment of acute bacterial exacerbations of chronic bronchitis.
    Amsden GW; Baird IM; Simon S; Treadway G
    Chest; 2003 Mar; 123(3):772-7. PubMed ID: 12628877
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Short-course therapy of gemifloxacin effective against pneumococcal pneumonia in mice.
    Bast DJ; Dresser L; Duncan CL; Walker SE; Mandell LA; Low DE; de Azavedo JC
    J Chemother; 2006 Dec; 18(6):634-40. PubMed ID: 17267342
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High doses of levofloxacin vs moxifloxacin against staphylococcal experimental foreign-body infection: the effect of higher MIC-related pharmacokinetic parameters on efficacy.
    Murillo O; Pachón ME; Euba G; Verdaguer R; Tubau F; Cabellos C; Cabo J; Gudiol F; Ariza J
    J Infect; 2009 Mar; 58(3):220-6. PubMed ID: 19217166
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetic/pharmacodynamic modelling of the bactericidal activity of free lung concentrations of levofloxacin and gatifloxacin against Streptococcus pneumoniae.
    Tasso L; de Andrade C; Dalla Costa T
    Int J Antimicrob Agents; 2011 Oct; 38(4):307-13. PubMed ID: 21802907
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Disposition kinetics and dosage regimen of levofloxacin on concomitant administration with paracetamol in crossbred calves.
    Dumka VK
    J Vet Sci; 2007 Dec; 8(4):357-60. PubMed ID: 17993749
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ex vivo antibacterial activity of levofloxacin against Escherichia coli and its pharmacokinetic profile following intravenous and oral administrations in broilers.
    Lee HK; DeVito V; Vercelli C; Tramuta C; Nebbia P; Re G; Kovalenko K; Giorgi M
    Res Vet Sci; 2017 Jun; 112():26-33. PubMed ID: 28113087
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Levofloxacin and macrolides in chronic bronchitis exacerbation: comparative analysis of the treatment efficacy and nonrelapsing periods].
    Dvoretskiĭ LI; Dubrovskaia NV; Grudinina SA; Filimonova OIu; Sidorenko SV; Iakovlev SV
    Antibiot Khimioter; 2007; 52(7-8):21-31. PubMed ID: 18986021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.